CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.

Recent evidence suggests that breast cancer and other solid tumors possess a rare population of cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. We report here the development of a strategy to target these breast cancer stem cells (CSCs) through blockade of the IL-8 receptor CXCR1. CXCR1 blockade using either a CXCR1-specific blocking antibody or repertaxin, a small-molecule CXCR1 inhibitor, selectively depleted the CSC population in 2 human breast cancer cell lines in vitro. Furthermore, this was followed by the induction of massive apoptosis in the bulk tumor population via FASL/FAS signaling. The effects of CXCR1 blockade on CSC viability and on FASL production were mediated by the FAK/AKT/FOXO3A pathway. In addition, repertaxin was able to specifically target the CSC population in human breast cancer xenografts, retarding tumor growth and reducing metastasis. Our data therefore suggest that CXCR1 blockade may provide a novel means of targeting and eliminating breast CSCs.

[1]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[2]  David A Hess,et al.  High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability , 2009, Journal of cellular and molecular medicine.

[3]  T. Taguchi,et al.  Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers , 2009, Clinical Cancer Research.

[4]  M. Wicha,et al.  Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling , 2009, PLoS biology.

[5]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[6]  M. Wicha,et al.  Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. , 2009, Cancer research.

[7]  P. Schultz,et al.  The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations , 2009, Proceedings of the National Academy of Sciences.

[8]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[9]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[10]  Anna E. Lokshin,et al.  Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties , 2008, PloS one.

[11]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[12]  J. Lieberman,et al.  let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.

[13]  D. Santini,et al.  IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. , 2007, The Journal of clinical investigation.

[14]  D. Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[15]  M. Wicha,et al.  Selective Targeting of Cancer Stem Cells , 2007, BioDrugs.

[16]  M. Todaro,et al.  Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. , 2007, Cell stem cell.

[17]  Aleksandar Dakic,et al.  Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells , 2007, Science.

[18]  C. Brisken,et al.  Stem Cells and the Stem Cell Niche in the Breast: An Integrated Hormonal and Developmental Perspective , 2007, Stem Cell Reviews.

[19]  M. Bhat,et al.  Bystander killing of breast cancer MCF‐7 cells by MDA‐MB‐231 cells exposed to 5‐fluorouracil is mediated via Fas , 2007, Journal of cellular biochemistry.

[20]  Mieke Schutte,et al.  Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines , 2007, Molecular Cancer Research.

[21]  Frank Pajonk,et al.  The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. , 2006, Journal of the National Cancer Institute.

[22]  Daniel Birnbaum,et al.  Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers , 2006, Clinical Cancer Research.

[23]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[24]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[25]  P. Allen,et al.  Inflammatory arthritis requires Foxo3a to prevent Fas ligand–induced neutrophil apoptosis , 2005, Nature Medicine.

[26]  Pietro Ghezzi,et al.  Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Hanks,et al.  Focal Adhesion Kinase Suppresses Apoptosis by Binding to the Death Domain of Receptor-Interacting Protein , 2004, Molecular and Cellular Biology.

[28]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[29]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  F. Bertucci,et al.  Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. , 2002, The American journal of pathology.

[31]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[32]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[33]  Brian A. Hemmings,et al.  Protein Kinase SGK Mediates Survival Signals by Phosphorylating the Forkhead Transcription Factor FKHRL1 (FOXO3a) , 2001, Molecular and Cellular Biology.

[34]  K. Tartaro,et al.  Roles of Fas and Fas ligand during mammary gland remodeling. , 2000, The Journal of clinical investigation.

[35]  S. Schwartz,et al.  Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells , 2000, Nature Medicine.

[36]  C. Dinney,et al.  Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  Mark Shackleton,et al.  Efficient tumour formation by single human melanoma cells , 2008 .

[38]  R. Ransohoff.  The MHP36 line of murine neural stem cells expresses functional CXCR1 chemokine receptors that initiate chemotaxis in vitro. , 2007, Journal of neuroimmunology.

[39]  M. Wicha,et al.  Regulation of Mammary Stem/progenitor Cells by Pten/ Akt/b-catenin Signaling , 2022 .